Cholecalciferol API Manufacturers & Suppliers

Cholecalciferol is used to treat or prevent vitamin D deficiency and disorders of calcium–phosphate balance. Clinical uses include refractory rickets, hypoparathyroidism, familial hypophosphatemia, osteoporosis, and conditions associated with impaired mineral homeostasis such as chronic kidney disease. It serves as a precursor to calcitriol, which regulates intestinal mineral absorption, renal calcium handling, and bone remodeling.

Cholecalciferol belongs to the following therapeutic categories: Alimentary Tract and Metabolism, Bone Density Conservation Agents, Calcium-Regulating Hormones and Agents, Cholecalciferol, antagonists & inhibitors, Cholestanes. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for Cholecalciferol: Cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia, Concurrently, as one of the most commonly utilized forms of vitamin D, Cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

Most individuals naturally generate adequate amounts of vitamin D through ordinary dietary intake of vitamin D (in some foods like eggs, fish, and cheese) and natural photochemical conversion of the vitamin D3 precursor 7-dehydrocholesterol in the skin via exposure to sunlight . Conversely, vitamin D deficiency can often occur from a combination of insufficient exposure to sunlight, inadequate dietary intake of vitamin D, genetic defects with endogenous vitamin D receptor, or even severe liver or kidney disease . Such deficiency is known for resulting in conditions like rickets or osteomalacia, all of which reflect inadequate mineralization of bone, enhanced compensatory skeletal demineralization, resultant decreased calcium ion blood concentrations, and increases in the production and secretion of parathyroid hormone . Increases in parathyroid hormone stimulate the mobilization of skeletal calcium and the renal excretion of phosphorus . This enhanced mobilization of skeletal calcium leads towards porotic bone conditions . Ordinarily, while vitamin D3 is made naturally via photochemical processes in the skin, both itself and vitamin D2 can be found in various food and pharmaceutical sources as dietary supplements. The principal biological function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet . At the liver, vitamin D3 or D2 is hydroxylated to 25-hydroxyvitamin D and then finally to the primary active metabolite 1,25-dihydroxyvitamin D in the kidney via further hydroxylation . This final metabolite binds to endogenous vitamin d receptors, which results in a variety of regulatory roles - including maintaining calcium balance, the regulation of parathyroid hormone, the promotion of the renal reabsorption of calcium, increased intestinal absorption of calcium and phosphorus, and increased calcium and phosphorus mobilization of calcium and phosphorus from bone to plasma to maintain balanced levels of each in bone and the plasma . In particular, calcitriol interacts with vitamin D receptors in the small intestine to enhance the efficiency of intestinal calcium and phosphorous absorption from about 10-15% to 30-40% and 60% increased to 80%, respectively . Furthermore, calcitriol binds with vitamin D receptors in osteoblasts to stimulate a receptor activator of nuclear factor kB ligand (or RANKL) which subsequently interacts with receptor activator of nuclear factor kB (NFkB) on immature preosteoclasts, causing them to become mature bone-resorbing osteoclasts . Such mature osteoclasts ultimately function in removing calcium and phosphorus from bone to maintain blood calcium and phosphorus levels . Moreover, calcitriol also stimulates calcium reabsorption from the glomerular filtrate in the kidneys . Additionally, it is believed that when calcitriol binds with nuclear vitamin D receptors, that this bound complex itself binds to retinoic acid X receptor (RXR) to generate a heterodimeric complex that consequently binds to specific nucleotide sequences in the DNA called vitamin D response elements . When bound, various transcription factors attach to this complex, resulting in either up or down-regulation of the associated gene's activity. It is thought that there may be as much as 200 to 2000 genes that possess vitamin D response elements or that are influenced indirectly to control a multitude of genes across the genome . It is in this way that Cholecalciferol is believed to function in regulating gene transcription associated with cancer risk, autoimmune disorders, and cardiovascular disease linked to vitamin D deficiency . In fact, there has been some research to suggest calcitriol may also be able to prevent malignancies by inducing cellular maturation and inducing apoptosis and inhibiting angiogenesis, exhibit anti-inflammatory effects by inhibiting foam cell formation and promoting angiogenesis in endothelial colony-forming cells in vitro, inhibit immune reactions by enhancing the transcription of endogenous antibiotics like cathelicidin and regulate the activity and differentiation of CD4+ T cells, amongst a variety of other proposed actions .

Excess Cholecalciferol can cause hypervitaminosis D, leading to hypercalcemia with early neuromuscular and gastrointestinal symptoms and potential progression to renal impairment, soft‑tissue calcification, and seizures. Maternal overexposure has been linked to fetal and neonatal hypercalcemia and related developmental or cardiovascular effects, and high intake during lactation may raise infant calcium levels. Toxicity generally reflects excessive dosing rather than ordinary nutritional exposure.

Cholecalciferol is highly lipophilic and water‑insoluble, so it is typically formulated in oily or solubilized vehicles to ensure adequate dispersion and oral absorption. Because it is sensitive to light and oxidation, processing and storage should minimize exposure to UV light and oxygen. Its fat solubility supports use of lipid-based or emulsified oral dosage forms, and handling should maintain protection from degradative conditions throughout manufacturing.

Cholecalciferol is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Yes. Oral Cholecalciferol is highly lipophilic and sensitive to light and oxidation, so formulations require protection from UV exposure and oxygen during manufacturing and storage. Its poor water solubility favors incorporation into oily or solubilized vehicles to maintain stability. Food‑dependent absorption can occur, but this does not change the intrinsic stability concerns.